New combo therapy shows promise for tough lung cancers
NCT ID NCT03083041
First seen Mar 05, 2026 · Last updated May 07, 2026 · Updated 9 times
Summary
This study tested a combination of two drugs, SHR-1210 and apatinib, in 210 people with advanced non-small cell lung cancer that had stopped responding to earlier treatments. The goal was to see if the combination was safe and could shrink tumors. Participants received the drugs intravenously and by mouth, and their tumors were monitored for response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, 200433, China
Conditions
Explore the condition pages connected to this study.